Table 4. Correlation between clinicopathological factors and expression of MDR1/P-gp and MRP-1 protein in all melanoma specimens analysed.
| Characteristics | No. of cases | MDR P-gp (%) | P | No. of cases | MRP-1 (%) | P |
|---|---|---|---|---|---|---|
| Age (years) | ||||||
| <59 | 34/65 | 52.3 | 0.241 | 43/65 | 66.2 | 0.809 |
| ⩾59 | 43/69 | 62.3 | 47/69 | 68.1 | ||
| Gender | ||||||
| Male | 30/51 | 58.8 | 0.803 | 39/51 | 76.5 | 0.072 |
| Female | 47/83 | 56.6 | 51/83 | 61.4 | ||
| Lymph node spread | ||||||
| Negative | 50/98 | 51.0 | 0.013* | 57/98 | 58.2 | <0.0005* |
| Positive | 27/36 | 75.0 | 33/36 | 91.7 | ||
| Clark's level | ||||||
| II and III | 20/41 | 48.8 | 0.251 | 19/41 | 46.3 | 0.051 |
| IV and V | 17/27 | 63.0 | 19/27 | 70.3 | ||
| Clark's level | ||||||
| II, III, IV | 32/62 | 51.6 | 0.136 | 32/62 | 51.6 | 0.032* |
| V | 5/6 | 83.3 | 6/6 | 100 | ||
| Breslow thickness | ||||||
| <1 mm | 14/30 | 46.7 | 0.052 | 13/30 | 43.3 | 0.107 |
| 1–4 mm | 11/28 | 39.3 | 16/28 | 57.1 | ||
| >4 mm | 16/22 | 72.7 | 11/22 | 50.0 | ||
| Relapse | ||||||
| Relapse within 5 years | 17/31 | 0.260 | 18/31 | 0.252 | ||
Abbreviations: MDR1/P-gp=multi-drug resistance; MRP=multidrug resistance-associated protein. P values from χ2 analyses; *indicates significant parameter; Clark's score – information was available for 68 of 134 cases; Breslow's thickness – information was available for 80 of 134 cases.